EMCURE PHARMACEUTICALS Q2 FY27 CONCALL: RAISES FY27 REVENUE GROWTH GUIDANCE TO OVER 20%, TARGETS 75–100 BPS EBITDA MARGIN EXPANSION; EXPECTS LOW-TEENS INDIA GROWTH, STRONG ZUVENTUS RECOVERY & NET CASH BY FY28